Skip to Content

Xofigo Approval History

  • FDA approved: Yes (First approved May 15th, 2013)
  • Brand name: Xofigo
  • Generic name: radium Ra 223 dichloride
  • Dosage form: Injection
  • Company: Bayer HealthCare Pharmaceuticals Inc.
  • Treatment for: Prostate Cancer

Xofigo (radium 223 dichloride) is an alpha particle-emitting radioactive therapeutic agent indicated for the treatment of patients with castration-resistant prostate cancer.

Development History and FDA Approval Process for Xofigo

May 15, 2013Approval FDA Approves Xofigo for Advanced Prostate Cancer

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.